Mavenclad (Cladribine)

Cladribine is a purine nucleoside analog that is taken up by lymphocytes and incorporated into their DNA. This causes DNA damage and triggers apoptosis of B and T cells, selectively reducing the immune cells that drive inflammatory activity in multiple sclerosis.

The dosing regimen for Mavenclad is determined by the prescribing physician based on the patient’s clinical profile and regulatory guidelines. Patients should follow the specific schedule and monitoring plan provided by their healthcare professional.

The safety of Mavenclad in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women, and effective contraception is recommended during treatment and for a defined period after the last dose. Breastfeeding decisions should be discussed with a healthcare provider.

To order Mavenclad, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mavenclad differs from many disease‑modifying therapies by providing intermittent oral dosing that leads to selective lymphocyte depletion, whereas other agents may require continuous administration or injectable routes. Its efficacy in reducing relapse rates is comparable to some injectable therapies, but safety profiles and monitoring requirements vary.

Mavenclad tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mavenclad is taken orally as a tablet. The prescribed dosing schedule typically involves short treatment courses separated by drug‑free intervals, allowing for periodic monitoring of lymphocyte counts and clinical response. Exact administration instructions are provided by the prescriber.

The most serious risks include profound lymphopenia, which can increase susceptibility to infections such as herpes zoster, and rare reports of malignancies. Patients should be monitored regularly for blood count changes and signs of infection, and any concerning symptoms should be reported promptly.

Mavenclad is contraindicated in individuals with active infections, severe immunodeficiency, known hypersensitivity to cladribine, and pregnant or breastfeeding women. Patients with significant renal impairment may require special consideration, and the drug should be avoided in those receiving other potent immunosuppressants without medical supervision.